Stellar Ocean Medical Secures Over RMB 100 Million Series B Financing to Accelerate Global Expansion of Single-Use Endoscopy Solutions

VCBeat has learned that recently, MacroLux Medical Technology Co., Ltd. (hereinafter referred to as “MacroLux”) announced the completion of its Series B financing round, exceeding RMB 100 million, led byYuanBio Venture CapitalLead Investor, Existing ShareholderLegend Capital, Dalton VentureCapitalContinuous infusion,HAOYUE CAPITALServed as the exclusive financial advisor. This round of financing will help MacroLux further expand production capacity, accelerate new product development and global market expansion, and drive its rapid growth in the field of single-use endoscopes.

MacroLux was established in October 2020. Its founding team hails from leading medical device companies both in China and abroad, boasting over a decade of experience in the R&D, global marketing, and production management of minimally invasive surgical products. Committed to becoming an innovative leader in endoscopic interventional diagnosis and treatment, MacroLux’s core product line of single-use electronic endoscopes covers urology, respiratory care, ICU, gynecology, gastroenterology, and other fields. The company has already entered markets in China, the United States, Europe, and the Asia-Pacific region.

Endoscopic interventional diagnosis and treatment are widely used in gastroenterology, urology, pulmonology, otolaryngology, gynecology, and other fields. Traditional reusable flexible endoscopes pose challenges such as cross-infection risks, high acquisition costs, and low efficiency. In response to these needs, single-use electronic endoscopes have emerged, effectively addressing cross-infection concerns. Their ready-to-use design ensures that the endoscope is always in optimal condition, significantly improving surgical efficiency.

In addition, single-use endoscopes can significantly reduce hospitals' procurement costs and promote the widespread adoption of endoscopic diagnostic and therapeutic technologies. Consequently, in recent years, the penetration rate of single-use electronic endoscopes has risen rapidly, gradually replacing reusable endoscopes in certain departments.

MacroLux’s disposable electronic endoscope delivers superior performance in core areas such as image clarity and ease of operation, better meeting the demands of clinicians. Since its launch, it has gained widespread market recognition, thereby attracting repeated investment from leading institutional investors.

Zhang Weiqiang, Founder of MacroLuxStatement: We extend our gratitude to YuanBio Venture Capital for its trust in MacroLux, to our existing shareholders Legend Capital and Dalton Venture for their unwavering support, and to our financing partner HAOYUE CAPITAL for its assistance. The market for single-use electronic endoscopes is an early-stage, well-defined, and rapidly growing sector. Within just a few years, MacroLux has completed its product portfolio layout across urology, respiratory, gynecology, and gastroenterology specialties. Our products offer leading performance and have gained widespread recognition from customers and the industry. Meanwhile, we are accelerating our global market entry, propelling the company into a phase of rapid revenue growth. The ample funding will enable us to further expand production capacity, accelerate new product R&D, and broaden our global market presence, thereby delivering more and better clinical solutions to customers worldwide.

Gu Leimin, Partner at YuanBio Venture CapitalStatement: Minimally invasive medicine represents an inevitable trajectory in the advancement of medical technology, leading the future direction of healthcare. Disposable endoscopes are not only essential tools for minimally invasive surgeries but also constitute a potential multi-billion-dollar market segment within the global healthcare industry. With its forward-looking vision, YuanBio Venture Capital has strategically invested in numerous niche sectors within the field of minimally invasive medicine, placing particular emphasis on disposable endoscopes. In this domain, MacroLux has emerged as a shining star, distinguished by its international perspective and extensive experience. The team boasts a comprehensive R&D platform for endoscopic technologies, a robust product pipeline, and a uniquely crafted commercialization strategy for both domestic and overseas markets. MacroLux’s ability to stand out in the highly competitive landscape of disposable endoscopes is attributed not only to the team’s strategic insight and execution capabilities but also to their unwavering commitment to efficient implementation and sense of mission. We are deeply honored to collaborate with the team led by Mr. Zhang Weiqiang and look forward to jointly driving the development of more innovative products and accelerating their global market penetration, thereby delivering benefits to patients and healthcare providers worldwide.

Zhou Quan, Managing Director at Legend CapitalStatement: Congratulations to the company on completing its new round of financing, and welcome to our new partners. In less than two years since the collaboration began, the team has demonstrated professional and efficient operational capabilities, driving the company to achieve the expected leap from innovative product development to global commercialization. Single-use endoscopy is an emerging track in which Chinese enterprises are poised to maintain global leadership. We look forward to the company’s growth into a brand manufacturer with global influence.

Fu Ying, Investment Director at Dalton VentureDalton Venture stated: “We firmly believe that the disposable electronic endoscope market is in a phase of rapid growth. As an investor in MacroLux’s first two funding rounds, we have witnessed the team demonstrate robust capabilities in rapidly responding to market-driven R&D demands, strong supply chain integration, and excellent competitiveness in overseas markets. We look forward to MacroLux becoming a leader in the disposable endoscopy sector.”

Ding Yameng, Founding Managing Partner and Chief Operating Officer of HAOYUE CAPITALStatement: We are honored to have assisted MacroLux in completing this round of financing. With an industry-leading R&D and commercialization team, a global strategic plan, a differentiated endoscopy R&D platform, and exceptional mass production capabilities, we believe this financing will enhance MacroLux’s capabilities in R&D, production, and sales, laying a solid foundation for the company’s rapid future growth. We remain firmly bullish on MacroLux and are committed to growing alongside the company.

YuanBio Venture Capital is an investment firm focused on the early and growth stages of the healthcare sector. Headquartered in Suzhou BioBAY, it maintains a global reach. To date, YuanBio has invested in over 180 outstanding companies in the life and health sectors, covering four key areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as healthcare services. The firm has achieved substantial investment returns, with 19 of its portfolio companies listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanBio has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. By bringing together seasoned professional investors and a world-class team of scientific advisors, YuanBio possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging our professionalism, focus, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

Legend Capital, established in April 2001, is a fund management company under Legend Holdings that specializes in early-stage venture capital and growth-stage private equity investments. Over the past two decades, Legend Capital has adhered to international standards, creating best practices in fund operations and management. Through its proactive value-added service system, the firm drives innovative growth for portfolio companies, consistently delivering strong investment returns across multiple sectors while promoting industrial advancement and social development in China. With the vision of “becoming an investment firm with global influence,” Legend Capital upholds the core value of “Wealth with Integrity” and actively fulfills its social responsibilities.

Legend Capital has long focused on investments in the medical device and diagnostics sectors, having invested in a series of leading companies across various sub-segments within these fields.

Dalton Venture focuses on early-stage investments in the healthcare industry, with a particular emphasis on innovative medical technologies, and has served as an early investor in numerous projects featuring China’s first-of-their-kind technologies. The core team at Dalton Venture hails from the healthcare sector, having successfully incubated early-stage startups and founded and managed public companies with market capitalizations exceeding RMB 10 billion. Adhering to the philosophy of being not only a value discoverer but also a value creator, Dalton Venture supports corporate growth through comprehensive post-investment empowerment. The firm has repeatedly received accolades such as Top 100 VC Firms by VCBeat and Top 20 in Medical Devices.

HAOYUE CAPITALFounded in January 2014, HAOYUE CAPITAL is a leading industry-focused investment bank in China specializing in the healthcare sector. Headquartered in Shanghai, the firm maintains regional offices in Beijing and Shenzhen. Committed to empowering growth through capital and research-driven insights, HAOYUE CAPITAL helps outstanding Chinese healthcare enterprises successfully access the capital markets, thereby creating value-added benefits for its clients. The partnership team at HAOYUE CAPITAL comprises seasoned investment bankers with extensive experience in China’s healthcare industry.The firm closely monitors dynamics and trends in the healthcare investment market over the long term. Its research coverage and transaction scope span multiple sub-sectors, including innovative pharmaceuticals, innovative medical devices, IVD and life sciences, health services, and smart healthcare. As of 2023, HAOYUE CAPITAL had completed nearly 400 projects, with cumulative transaction values exceeding USD 10 billion; this included over 50 M&A and restructuring deals, totaling more than USD 5 billion. In 2023 alone, the firm executed nearly 50 complex transactions involving private equity financing, M&A integration, and services for listed companies, with a total transaction value amounting to several billion USD, maintaining its comprehensive leadership across various sub-sectors of the healthcare industry.

Recommended Reading: “[Exclusive] MacroLux Completes Tens of Millions in A+ Round Financing; Exclusive Interview with Founder Zhang Weiqiang”